Ceftaroline: Difference between revisions
(Created page with "__NOTOC__ {{Ceftaroline}} {{CMG}};{{AE}}{{AK}} ==Overview== Ceftaroline fosamil (INN) /sɛfˈtærɵliːn/, brand name Teflaro in the US and Zinforo in Europe, is an advanced-...") |
No edit summary |
||
| Line 24: | Line 24: | ||
'''| [[Ceftaroline overdosage|Overdosage]]''' | '''| [[Ceftaroline overdosage|Overdosage]]''' | ||
'''| [[Ceftaroline dosage and administration|Dosage and Administration]]''' | '''| [[Ceftaroline dosage and administration|Dosage and Administration]]''' | ||
'''| [[Ceftaroline | '''| [[Ceftaroline clinical studies|Clinical Studies]]''' | ||
'''| [[Ceftaroline how supplied|How Supplied]]''' | '''| [[Ceftaroline how supplied|How Supplied]]''' | ||
'''| [[Ceftaroline labels and packages|Labels and Packages]]''' | '''| [[Ceftaroline labels and packages|Labels and Packages]]''' | ||
Revision as of 08:25, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Ceftaroline fosamil (INN) /sɛfˈtærɵliːn/, brand name Teflaro in the US and Zinforo in Europe, is an advanced-generation[1] cephalosporinantibiotic. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria. It retains the activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria. It is currently being investigated for community-acquired pneumonia[2] and complicated skin and skin structure infection.
Category
Cephalosporins, third generation.
US Brand Names
TEFLARO®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Clinical Studies | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001lbl.pdf